Patents by Inventor Maninder S. Hora
Maninder S. Hora has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7807142Abstract: Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an acceptable pH range for stability of the polypeptide. Methods for increasing stability of a polypeptide in a liquid pharmaceutical composition and for increasing storage stability of such a pharmaceutical composition are also provided.Type: GrantFiled: December 5, 2005Date of Patent: October 5, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Bao-Lu Chen, Maninder S. Hora
-
Patent number: 7662369Abstract: Stabilized pharmaceutical formulations comprising IFN-? and highly purified mannitol are provided. The highly purified mannitol stabilizes the compositions by reducing the formation of IFN-? adducts in comparison with IFN-? formulated with mannitol that has not been highly purified. Methods for increasing the stability of IFN-? or a variant thereof in a liquid or lyophilized composition and for increasing storage stability of such a composition are also provided.Type: GrantFiled: July 22, 2005Date of Patent: February 16, 2010Assignee: Novartis AGInventors: Sidney N. Wolfe, Maninder S. Hora
-
Publication number: 20080281084Abstract: Compositions are described that are suitable for formulating TFPI. Solubilizers and stabilizers facilitate the preparation of pharmaceutically acceptable compositions of TFPI at various concentrations.Type: ApplicationFiled: April 5, 2007Publication date: November 13, 2008Applicants: Novartis Vaccines and Diagnostics, Inc., G. D. Searle LLCInventors: Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F. Halenbeck, Kirk Johnson, Bao-Lu Chen, Raisharan K. Rana, Maninder S. Hora, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
-
Publication number: 20080171071Abstract: A highly concentrated, low salt-containing, biologically active syrup form of IGF-I or variant thereof and methods for its preparation are provided. This novel syrup form of IGF-I has an IGF-I concentration of at least about 250 mg/ml, a density of about 1.0 g/ml to about 1.2 g/ml, and a viscosity of about 13,000 centipoise (cps) to about 19,000 cps, as measured at ambient temperature (23° C.). The IGF-I syrup is prepared by precipitating or partitioning IGF-I from solution, preferably by adjusting the solution pH or by use of a solubility enhancer to concentrate IGF-I in solution followed by removal of the solubility enhancer. The precipitated syrup is useful as a means of storing IGF-I in a stable form and as a means of preparing compositions comprising biologically active IGF-I. Pharmaceutical compositions and kits comprising this concentrated IGF-I syrup are provided.Type: ApplicationFiled: December 17, 2007Publication date: July 17, 2008Applicant: Chiron CorporationInventors: Bret A. Shirley, Maninder S. Hora
-
Patent number: 7335639Abstract: A highly concentrated, low salt-containing, biologically active syrup form of IGF-I or variant thereof and methods for its preparation are provided. This novel syrup form of IGF-I has an IGF-I concentration of at least about 250 mg/ml, a density of about 1.0 g/ml to about 1.2 g/ml, and a viscosity of about 13,000 centipoise (cps) to about 19,000 cps, as measured at ambient temperature (23° C.). The IGF-I syrup is prepared by precipitating or partitioning IGF-I from solution, preferably by adjusting the solution pH or by use of a solubility enhancer to concentrate IGF-I in solution followed by removal of the solubility enhancer. The precipitated syrup is useful as a means of storing IGF-I in a stable form and as a means of preparing compositions comprising biologically active IGF-I. Pharmaceutical compositions and kits comprising this concentrated IGF-I syrup are provided.Type: GrantFiled: August 2, 2005Date of Patent: February 26, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Bret A. Shirley, Maninder S. Hora
-
Patent number: 7226757Abstract: Compositions are described that are suitable for formulating TFPI. Solubilizers and stabilizers facilitate the preparation of pharmaceutically acceptable compositions of TFPI at various concentrations.Type: GrantFiled: January 24, 2006Date of Patent: June 5, 2007Assignees: G.D. Searle LLC, Novartis Vaccines and Diagnostics, Inc.Inventors: Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F. Halenbeck, Kirk Johnson, Bao-Lu Chen, Raisharan K. Rana, Maninder S. Hora, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
-
Patent number: 7067485Abstract: A highly concentrated, low salt-containing, biologically active syrup form of IGF-I or variant thereof and methods for its preparation are provided. This novel syrup form of IGF-I has an IGF-I concentration of at least about 250 mg/ml, a density of about 1.0 g/ml to about 1.2 g/ml, and a viscosity of about 13,000 centipoise (cps) to about 19,000 cps, as measured at ambient temperature (23° C.). The IGF-I syrup is prepared by precipitating or partitioning IGF-I from solution, preferably by adjusting the solution pH or by use of a solubility enhancer to concentrate IGF-I in solution followed by removal of the solubility enhancer. The precipitated syrup is useful as a means of storing IGF-I in a stable form and as a means of preparing compositions comprising biologically active IGF-I. Pharmaceutical compositions and kits comprising this concentrated IGF-I syrup are provided.Type: GrantFiled: November 6, 1998Date of Patent: June 27, 2006Assignee: Chiron CorporationInventors: Bret A. Shirley, Maninder S. Hora
-
Patent number: 7030086Abstract: Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an acceptable pH range for stability of the polypeptide. The compositions are near isotonic. Methods for increasing stability of a polypeptide in a liquid pharmaceutical composition and for increasing storage stability of such a pharmaceutical composition are also provided.Type: GrantFiled: November 18, 2002Date of Patent: April 18, 2006Assignee: Chiron CorporationInventors: Bao-Lu Chen, Maninder S. Hora
-
Patent number: 6994847Abstract: Stabilized pharmaceutical formulations comprising IFN-? and highly purified mannitol are provided. The highly purified mannitol stabilizes the compositions by reducing the formation of IFN-? adducts in comparison with IFN-? formulated with mannitol that has not been highly purified. Methods for increasing the stability of IFN-? or a variant thereof in a liquid or lyophilized composition and for increasing storage stability of such a composition are also provided.Type: GrantFiled: November 7, 2001Date of Patent: February 7, 2006Assignee: Chiron CorporationInventors: Sidney N. Wolfe, Maninder S. Hora
-
Publication number: 20030180253Abstract: Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an acceptable pH range for stability of the polypeptide. The compositions are near isotonic. Methods for increasing stability of a polypeptide in a liquid pharmaceutical composition and for increasing storage stability of such a pharmaceutical composition are also provided.Type: ApplicationFiled: November 18, 2002Publication date: September 25, 2003Applicant: Chiron CorporationInventors: Bao-Lu Chen, Maninder S. Hora
-
Publication number: 20030109427Abstract: A highly concentrated, low salt-containing, biologically active syrup form of IGF-I or variant thereof and methods for its preparation are provided. This novel syrup form of IGF-I has an IGF-I concentration of at least about 250 mg/ml, a density of about 1.0 g/ml to about 1.2 g/ml, and a viscosity of about 13,000 centipoise (cps) to about 19,000 cps, as measured at ambient temperature (23° C.). The IGF-I syrup is prepared by precipitating or partitioning IGF-I from solution, preferably by adjusting the solution pH or by use of a solubility enhancer to concentrate IGF-I in solution followed by removal of the solubility enhancer. The precipitated syrup is useful as a means of storing IGF-I in a stable form and as a means of preparing compositions comprising biologically active IGF-I. Pharmaceutical compositions and kits comprising this concentrated IGF-I syrup are provided.Type: ApplicationFiled: November 6, 1998Publication date: June 12, 2003Inventors: BRET A. SHIRLEY, MANINDER S. HORA
-
Patent number: 6525102Abstract: Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an acceptable pH range for stability of the polypeptide. The compositions are near isotonic. Methods for increasing stability of a polypeptide in a liquid pharmaceutical composition and for increasing storage stability of such a pharmaceutical composition are also provided.Type: GrantFiled: October 3, 2000Date of Patent: February 25, 2003Assignee: Chiron CorporationInventors: Bao-Lu Chen, Maninder S. Hora
-
Publication number: 20020114782Abstract: Stabilized pharmaceutical formulations comprising IFN-&bgr; and highly purified mannitol are provided. The highly purified mannitol stabilizes the compositions by reducing the formation of IFN-&bgr; adducts in comparison with IFN-&bgr; formulated with mannitol that has not been highly purified. Methods for increasing the stability of IFN-&bgr; or a variant thereof in a liquid or lyophilized composition and for increasing storage stability of such a composition are also provided.Type: ApplicationFiled: November 7, 2001Publication date: August 22, 2002Applicant: Chiron CorporationInventors: Sidney N. Wolfe, Maninder S. Hora
-
Patent number: 6319896Abstract: A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins and aggregated proteins. Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.Type: GrantFiled: November 18, 1999Date of Patent: November 20, 2001Assignees: Chiron Corporation, G.D. Searle & Co.Inventors: Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F. Halenbeck, Kirk Johnson, Bao-Lu Chen, Rajsharan K. Rana, Maninder S. Hora, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
-
Patent number: 5888968Abstract: Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.Type: GrantFiled: October 22, 1996Date of Patent: March 30, 1999Assignee: Chiron CorporationInventors: Bao-Lu Chen, Rajsharan K. Rana, Maninder S. Hora
-
Patent number: 5078997Abstract: The present invention is a pharmaceutical composition for proteins which are not stably soluble. The preferred protein is IL-2 and the preferred composition includes amino acids, vitamins, polymers, fatty acids or low molecular weight acids.Type: GrantFiled: April 18, 1989Date of Patent: January 7, 1992Assignee: Cetus CorporationInventors: Maninder S. Hora, Nandini Katre, Kenneth A. Laderman